Recombinant DNA Advisory Committee - 03/1-2/93 
Others: 
Paul Aebersold, Food and Drug Administration 
Nicholas Akdemir, Genetic Therapy, Inc. 
French Anderson, University of Southern California 
Arthur Bank, Columbia University 
Jack Barber, Viagene, Inc. 
James Barrett, Genetic Therapy, Inc. 
Edward Beecham, Genetic Therapy, Inc. 
Arie Belldegrun, University of California, Los Angeles 
Anton Berns, Somatix Therapy Corporation 
Richard Boucher, University of North Carolina, Chapel Hill 
Liz Bowie, The Baltimore Sun 
G'dali Braverman, Act Up 
Malcolm Brenner, St. Jude Childrens Research Hospital 
Lou Bucalo, Ingenex, Inc. 
Barrie Carter, Targeted Genetics, Inc. 
Jan Chappell, Genetic Therapy, Inc. 
Ben Cheng, Act Up 
Yawen Chiang, Genetic Therapy, Inc. 
Shirley Clift, Somatix Corporation 
Larry Cohen, Somatix Corporation 
Kenneth Culver, University of Iowa 
Timothy Darrow, Duke University 
Krista Delviks, Hood College 
Wanda de Vlaminck, Avigen Corporation 
Ross Donehorner, Johns Hopkins University 
Jianyun Dong, University of Alabama 
Ron Dorazio, Genetix, Inc. 
Glen Dronoff, Johns Hopkins University 
Anne Driscoll, Novus Group 
Michelle Durand, The French Embassy 
David Ennist, Genetic Therapy, Inc. 
Susan Falen, Genetic Therapy, Inc. 
Mitchell Finer, Cell Genesys, Inc. 
Stacy Fitzsimmons, Cystic Fibrosis Foundation 
Suzanne Forry-Schaudies, Genetic Therapy, Inc. 
Jeffrey Fox, ASM News and Biotechnology 
Ray Frizzell, University of Alabama 
Siqang Fu, MD Anderson Cancer Research Center 
Ram Gamgavalli, Viagene, Inc. 
Richard Giles, University of Illinois 
Recombinant DNA Research, Volume 17 
[61] 
